In a 64-year-old man who had a stroke two months ago and is on lisinopril 20 mg daily, valsartan 160 mg daily (restarted after fatigue), low‑dose aspirin 81 mg daily, atorvastatin 40 mg daily, folic acid 1 mg daily, and has not been taking his metoprolol, what is the appropriate management for secondary stroke prevention and blood‑pressure control?

Management of Post-Stroke Patient with Polypharmacy and Medication Non-Adherence

You need to immediately discontinue valsartan and consolidate this patient's blood pressure regimen to lisinopril alone (or switch to a single ARB if ACE inhibitor is not tolerated), ensure metoprolol adherence, and verify the stroke etiology to guide appropriate antiplatelet therapy.

Critical Medication Issues to Address

1. Dangerous Dual RAAS Blockade

Your patient is currently taking both lisinopril 20 mg AND valsartan 160 mg, which constitutes dual renin-angiotensin-aldosterone system (RAAS) blockade. This combination:

• Increases risk of hypotension, hyperkalemia, and acute kidney injury 1
• Is not recommended for hypertension management 2
• Likely explains the patient's fatigue symptoms

Action: Stop valsartan immediately. The patient self-restarted this medication without your knowledge, creating a dangerous drug interaction.

2. Blood Pressure Management Strategy

According to the 2021 AHA/ASA Stroke Prevention Guidelines, intensive blood pressure control is critical for secondary stroke prevention 3. However, this must be achieved safely:

Recommended approach:

• Continue lisinopril 20 mg daily as monotherapy initially
• If BP remains uncontrolled after 2-4 weeks, add a calcium channel blocker (CCB) or thiazide-like diuretic (chlorthalidone preferred over HCTZ) 2
• Do NOT restart valsartan - combining ACE inhibitor + ARB provides no additional benefit and increases harm
• Target BP <130/80 mmHg for secondary stroke prevention 3

3. Beta-Blocker Non-Adherence

The patient has not picked up metoprolol from the pharmacy. This is concerning because:

• If prescribed for post-stroke cardiac indications (e.g., atrial fibrillation, heart failure, coronary disease), non-adherence increases recurrent stroke risk
• You need to determine why it was prescribed by cardiology

Action:

• Contact cardiology to clarify the indication for metoprolol
• If indicated for cardiac comorbidity, address barriers to adherence (cost, side effects, pill burden)
• If prescribed for hypertension alone and patient has no cardiac indication, consider discontinuing to simplify regimen

Secondary Stroke Prevention Optimization

4. Antiplatelet Therapy Assessment

The patient is on aspirin 81 mg daily, which is appropriate for long-term secondary prevention 3. However, you must verify:

Critical question: Was the patient started on dual antiplatelet therapy (DAPT) immediately after the stroke 2 months ago?

• If YES and still within 90 days: Continue aspirin + clopidogrel if stroke was due to large-vessel intracranial atherosclerosis 3
• If NO or >90 days post-stroke: Aspirin monotherapy is appropriate for most non-cardioembolic strokes 3
• If cardioembolic (atrial fibrillation): Patient should be on anticoagulation, NOT aspirin 3

Action: Review stroke workup from 2 months ago to determine etiology. If atrial fibrillation was detected, anticoagulation is mandatory.

5. Statin Therapy

Atorvastatin 40 mg is appropriate and should be continued 3, 4, 5. Recent evidence suggests high-intensity statins improve functional outcomes in older stroke patients without increased harm 4.

Consider: If LDL remains >70 mg/dL, uptitrate to atorvastatin 80 mg for more intensive lipid lowering 3.

6. Folic Acid

Continue folic acid 1 mg daily - this is reasonable for secondary prevention, particularly if homocysteine levels are elevated.

Immediate Action Plan

Within 1 week:

1. Stop valsartan immediately - call patient today to discontinue
2. Check basic metabolic panel - assess for hyperkalemia and renal function given dual RAAS blockade exposure
3. Measure blood pressure - assess current control on lisinopril alone
4. Contact cardiology - clarify metoprolol indication and coordinate care
5. Review stroke etiology - obtain records from hospitalization to confirm stroke subtype

Within 2-4 weeks:

1. Recheck BP - if >130/80 mmHg, add CCB (amlodipine 5-10 mg) or chlorthalidone 12.5-25 mg 2
2. Verify medication adherence - use pharmacy records and pill counts
3. Assess for occult atrial fibrillation - if stroke etiology unclear, consider extended cardiac monitoring 3

Within 3 months:

1. Multidisciplinary team approach - the 2021 guidelines strongly recommend team-based care with active medication adjustment by advanced practice providers, nurses, or pharmacists to improve risk factor control 3
2. Lifestyle counseling - low-salt Mediterranean diet and supervised physical activity 3

Common Pitfalls to Avoid

• Never combine ACE inhibitor + ARB - no benefit, increased harm
• Don't assume all antihypertensives are interchangeable - stroke patients need evidence-based combinations
• Don't ignore medication non-adherence - metoprolol non-adherence suggests broader adherence issues
• Don't forget to verify stroke etiology - treatment differs dramatically between cardioembolic vs. non-cardioembolic strokes
• Don't overlook patient self-medication - this patient restarted valsartan independently, indicating need for better patient education

The patient's fatigue was likely from excessive BP lowering due to dual RAAS blockade, not from valsartan alone. Simplifying to a single-agent RAAS blocker with appropriate add-on therapy will improve both tolerability and adherence while maintaining stroke prevention efficacy 3, 2.